Azenta (NASDAQ:AZTA – Get Free Report) and Quanterix (NASDAQ:QTRX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.
Institutional & Insider Ownership
99.1% of Azenta shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 10.9% of Azenta shares are held by company insiders. Comparatively, 1.5% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Azenta and Quanterix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
| Quanterix | 1 | 2 | 0 | 0 | 1.67 |
Risk & Volatility
Azenta has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
Profitability
This table compares Azenta and Quanterix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -20.63% | 1.18% | 0.97% |
| Quanterix | -80.25% | -26.09% | -19.03% |
Earnings & Valuation
This table compares Azenta and Quanterix”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $593.82 million | 2.31 | -$55.76 million | ($2.76) | -11.35 |
| Quanterix | $153.17 million | 0.83 | -$107.15 million | ($2.63) | -1.02 |
Azenta has higher revenue and earnings than Quanterix. Azenta is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.
Summary
Azenta beats Quanterix on 12 of the 14 factors compared between the two stocks.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
